Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 13/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426371 | 0.84 | MAPT (0.45) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL11953205 | 0.83 | ALDH1A1 (0.31) | SMN1; SMN2DYRK1AALDH1A1 | |
| SCHEMBL11953189 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL11953190 | 0.76 | DYRK1A (0.49) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL11953193 | 0.76 | MAPT (0.47) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL11953194 | 0.75 | DYRK1A (0.46) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL10249069 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTTP53KDM4ENPC1 | |
| SCHEMBL4544534 | 0.74 | KDM4E (0.46) | SMN1; SMN2MAPTTP53KDM4ENPC1 | |
| SCHEMBL11953192 | 0.74 | MAPT (0.50) | SMN1; SMN2MAPTTP53DYRK1AKDM4E | |
| SCHEMBL11953191 | 0.74 | DYRK1A (0.50) | SMN1; SMN2MAPTTP53DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742112-B2 | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | HAAO, DDT, ACHE | SMN1; SMN2 1085/4885MAPT 3493/4885TP53 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.